<DOC>
	<DOCNO>NCT00239174</DOCNO>
	<brief_summary>The purpose study assess effect SR147778 weight loss period 24 week prescribe hypocaloric diet obese patient . The secondary objective ass safety tolerability SR147778 ass effect SR147778 several secondary parameter ( waist , metabolic parameter ) period 24 week prescribe hypocaloric diet obese patient .</brief_summary>
	<brief_title>A Multicenter Study Evaluate Efficacy Safety Four Doses SR147778 Obese Patients</brief_title>
	<detailed_description />
	<mesh_term>Surinabant</mesh_term>
	<criteria>Patients must voluntarily sign informed consent , Patients must male female age 18 65 year , Patients must able follow verbal write instruction , Female patient childbearing potential ( premenopausal woman ) must confirm negative urine bhCG pregnancy test prior enrollment Baseline Visit . They must use acceptable double method birth control ( e.g. , oral implant contraceptive therapy , IUDs , plus barrier condom , diaphragm spermicide ) throughout study , accept repeat urine bhCG pregnancy test designate visit , Patients must BMI &gt; =30 &lt; = 40 screen Patients must stable weight ( variation le 5 kg 90 day precede Screening Visit ) Patients must show compliant dietary recommendation Screening Baseline Visits Patients ' physical examination , laboratory evaluation , 12lead ECG must within normal limit ( exception abnormality consider clinically insignificant opinion Investigator Center Monitor ) , within predefined limit hemoglobin ( &gt; = 11 g/dL ) , total cholesterolemia ( &lt; = 3 g/L , i.e . 7.7 mmol/L ) , triglyceridemia ( &lt; = 7 g/L , i.e . 7.9 mmol/L ) , fast glycemia ( &lt; = 1.6 g/L , i.e . 8.9 mmol/L ) , hemoglobin A1c ( &lt; = 8 % ) . Female patient pregnant lactating , Patients consider Investigator unsuitable candidate receipt investigational drug , Myocardial infarction within 12 month , Hypertension ( SBP &gt; 160 mmHg ; DBP &gt; 95 mmHg ) , Secondary hypertension Confirmed heart rate &lt; 60 beats/minute , Type 1 diabetes , treat insulin History presence pancreatitis , History presence clinically significant cardiac valve disorder abnormal cardiac echography . History concurrent DSMIV bulimia anorexia nervosa , Patients mental retardation clinically significant psychiatric disorder ( include organic mental disorder ) mild mood anxiety , History ( past six month ) concurrent DSMIV substance abuse dependence ( exclude nicotine caffeine far patient agrees modify her/his consumption throughout study ) , Severe multiple drug allergy , Any disorder may interfere drug absorption , metabolism distribution excretion , Presence clinically significant gastrointestinal , cardiovascular , hepatic , renal , hematological , endocrine , dermatological respiratory disease , medical condition might interfere evaluation study medication , Prolonged QTcB : &gt; 450 msec men &gt; 470 msec woman . Patients test positive illicit drug include urine drug screen ( THC ) Screening Baseline Visit . Patients positive benzodiazepine may admit , prescribed stable dose regimen . Patients test positive Screening Visit hepatitis B surface antigen , hepatitis C antibody , ALT and/or AST &gt; 2 x upper limit normal , Hb &lt; 11g/dL , fast glycemia &gt; 1.6 g/L i.e . 8.9 mmol/L , HbA1c &gt; 8 % , total cholesterolemia &gt; 3 g/L i.e . 7.7 mmol/L , TG &gt; 7 g/L i.e . 7.9 mmol/L , creatinemia &gt; 150 mmol/l Patients receive antiobesity drug drug ( ) preparation ( ) include herbal weight reduction within three month Screening Visit , Thyroid therapy , except replacement therapy . Patients use nicotine substitute take bupropion , Treated antidepressant neuroleptic drug ( ) one week within three month Screening Visit , Treated non selective systemic antihistamine Systemic corticosteroid inhale corticosteroid Treated potent inhibitor CYP3A4 Consuming 20 g/day alcohol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>obesity</keyword>
</DOC>